Last reviewed · How we verify
Juvenile idiopathic arthritis, extended oligoarthritis
Approved treatments
- Tasocitinib · Pfizer
- Xeljanz · Pfizer
Tofacitinib is a JAK inhibitor that prevents phosphorylation and activation of STATs. - Roactemra · Roche
Roactemra works by blocking the interleukin-6 receptor, a protein that plays a key role in inflammation. - Xeljanz · Pfizer
Tofacitinib inhibits Janus kinase enzymes to prevent STAT phosphorylation and activation. - TOFA
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Juvenile idiopathic arthritis, extended oligoarthritis patent landscape — cliff calendar, originator estates, attackable patents
- Juvenile idiopathic arthritis, extended oligoarthritis treatment landscape brief
- Juvenile idiopathic arthritis, extended oligoarthritis treatment updates RSS
Frequently asked questions about Juvenile idiopathic arthritis, extended oligoarthritis
What drugs treat Juvenile idiopathic arthritis, extended oligoarthritis?
Tracked treatments include Tasocitinib, Xeljanz, Roactemra, TOFA.
What is the treatment for Juvenile idiopathic arthritis, extended oligoarthritis?
Standard treatment for Juvenile idiopathic arthritis, extended oligoarthritis includes Tasocitinib, Xeljanz, Roactemra, TOFA. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Juvenile idiopathic arthritis, extended oligoarthritis patent cliff · Juvenile idiopathic arthritis, extended oligoarthritis CI report
- Treatment: Tasocitinib · Pfizer
- Treatment: Xeljanz · Pfizer
- Treatment: Roactemra · Roche
- Treatment: Xeljanz · Pfizer
- Treatment: TOFA
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing